SCHEMBL3783750

SCHEMBL3783750

CCOc1ccc(N)c(-c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
APOBEC3G Q9HC16 1/20 0.53
LMNA P02545 3/20 0.52
GAA P10253 1/20 0.52
MAPK10 P53779 1/20 0.52
TP53 P04637 3/20 0.49
CYP3A4 P08684 1/20 0.49
LTA4H P09960 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TTK P33981 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPT P10636 4/20 0.46
KDM4E B2RXH2 3/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 3/20 0.46
TSHR P16473 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3790223 0.86 LMNA (0.56) NPC1MEN1KMT2AAPOBEC3GLMNA
SCHEMBL3788470 0.86 TDP1 (0.60) NPC1MEN1KMT2AAPOBEC3GLMNA
SCHEMBL3786847 0.85 TP53 (0.62) NPC1MEN1KMT2AAPOBEC3GLMNA
SCHEMBL27449147 0.84 AGXT (0.52) LMNAGAAMAPK10TP53ALDH1A1
SCHEMBL3789175 0.84 MEN1 (0.54) NPC1MEN1KMT2AAPOBEC3GLMNA
SCHEMBL12493620 0.83 KMT2A (0.54) NPC1MEN1KMT2AAPOBEC3GLMNA
SCHEMBL27816394 0.83 ALDH1A1 (0.48) LMNAGAAMAPK10TP53L3MBTL1
SCHEMBL8266801 0.82 CHEK2 (0.44) LMNAALDH1A1MAPTHSD17B10SMN1; SMN2
SCHEMBL3793161 0.81 GSTP1 (0.57) LMNAGAACYP3A4L3MBTL1MAPT
SCHEMBL3785577 0.80 ALDH1A1 (0.50) NPC1MEN1KMT2ATP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210107871-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2021-04-15 US disclosed
US-20210107871-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2021-04-15 US disclosed
EP-3611161-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY National University Corporation Hokkaido University (JP) 2020-02-19 EP disclosed
EP-3611161-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY National University Corporation Hokkaido University (JP) 2020-02-19 EP disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 NPC1 724/4885MEN1 174/4885KMT2A 1474/4885
US-20210107871-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY FLNA, FLNB, BRI3BP NPC1 49/4885MEN1 4456/4885KMT2A 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.